Metabolic syndrome in patients with rheumatoid arthritis followed at a University Hospital in Northeastern Brazil

Oliveira, Brenda Maria Gurgel Barreto de; Medeiros, Marta Maria das Chagas; Cerqueira, João Victor Medeiros de; Quixadá, Raquel Telles de Souza; Oliveira, Ídila Mont’Alverne Xavier de

doi:10.1016/j.rbre.2015.08.016

Cited by 13 publications

(9 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[28] F o r P e e r R e v i e w 14 Chronic steroid use in patients with diverse autoimmune diseases has been associated with an increased risk of metabolic syndrome and cardiovascular disease due to its enhancement of plaque formation, arterial stiffness, insulin resistance and lipid levels. [29][30][31] Perversely, the suppression of inflammation by steroids may also decrease the risk of cardiovascular disease, although there is limited outcomes data to demonstrate this. No study has previously compared outcomes between patients with RA depending on their steroid use.…”

Section: Discussionmentioning

confidence: 99%

Percutaneous coronary intervention outcomes in patients with rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis

et al. 2020

View full text Add to dashboard Cite

Objective Patients with autoimmune rheumatic disease (AIRD) are at an increased risk of coronary artery disease. The present study sought to examine the prevalence and outcomes of AIRD patients undergoing percutaneous coronary intervention (PCI) from a national perspective. Methods All PCI-related hospitalizations recorded in the US National Inpatient Sample (2004–2014) were included, stratified into four groups: no AIRD, RA, SLE and SSc. We examined the prevalence of AIRD subtypes and assessed their association with in-hospital adverse events using multivariable logistic regression [odds ratios (OR) (95% CI)]. Results Patients with AIRD represented 1.4% (n = 90 469) of PCI hospitalizations. The prevalence of RA increased from 0.8% in 2004 to 1.4% in 2014, but other AIRD subtypes remained stable. In multivariable analysis, the adjusted odds ratio (aOR) of in-hospital complications [aOR any complication 1.13 (95% CI 1.01, 1.26), all-cause mortality 1.32 (1.03, 1.71), bleeding 1.50 (1.30, 1.74), stroke 1.36 (1.14, 1.62)] were significantly higher in patients with SSc compared with those without AIRD. There was no difference in complications between the SLE and RA groups and those without AIRD, except higher odds of bleeding in SLE patients [aOR 1.19 (95% CI 1.09, 1.29)] and reduced odds of all-cause mortality in RA patients [aOR 0.79 (95% CI 0.70, 0.88)]. Conclusion In a nationwide cohort of US hospitalizations, we demonstrate increased rates of all adverse clinical outcomes following PCI in people with SSc and increased bleeding in SLE. Management of such patients should involve a multiteam approach with rheumatologists.

show abstract

Section: Discussionmentioning

confidence: 99%

Percutaneous coronary intervention outcomes in patients with rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Evidence regarding the impact of MetS on RA is mixed. Several studies that assessed patients with RA with MetS showed this population is more likely to have higher Health Assessment Questionnaire (HAQ) scores than patients without MetS; however, other studies have not shown a significant difference 37‐41 . Two large‐scale studies that included 100 patients showed that MetS was associated with high systemic inflammatory markers, disease activity, and disability scores compared with patients with RA but without MetS 42,43 .…”

Section: Discussionmentioning

confidence: 99%

Systematic review and meta‐analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis

et al. 2021

View full text Add to dashboard Cite

Background Psoriatic arthritis (PsA), rheumatoid arthritis (RA) and psoriasis (PsO) are associated with systemic inflammation and increased cardiovascular mortality and morbidity. Metabolic syndrome (MetS) is associated with systemic inflammation, and conditions associated with MetS, such as obesity, are associated with difficulty in attaining minimal disease activity (MDA) in individuals with inflammatory arthritis. This systematic review aims to determine whether there is an increased prevalence of MetS in PsA populations compared with PsO and RA populations. Methods A systematic review was conducted to assess the prevalence of MetS in PsA, PsO, and RA populations following Preferred Reporting Items for Systematic Reviews and Meta‐analyses guidelines. The quality of the studies reviewed was assessed using the Joanna Briggs Institute Checklist for Prevalence Studies. Results The pooled prevalence of MetS in PsA populations was 0.46 ± 0.06 (95% CI 0.40‐0.51). In comparison, the prevalence of MetS in PsO and RA populations was 0.34 ± 0.03 (95% CI 0.32‐0.37) and 0.31 ± 0.04 (95% CI 0.27‐0.35), respectively. Patients with PsA were 1.62 ± 0.036 (95% CI 1.50‐1.74) and 1.66 ± 0.038 (95% CI 1.54‐1.79) times more likely to have MetS compared with PsO and RA populations. Conclusion The prevalence of MetS is significantly increased in PsA populations compared with PsO and RA populations. Further studies should be performed using a standardized definition of MetS in PsA, RA, and PsO populations to determine whether addressing the metabolic components in MetS offers any therapeutic benefits and in terms of attaining MDA and improving cardiovascular health.

show abstract

“…Nevertheless, AS patients with a higher disease activity score also had a higher prevalence of MetS, so, it can be considered that MetS is closely related to a chronic inflammatory state which can affect the disease activity in AS patients. 20 showed that age was an independent predictor of MetS in patients with RA. Obesity is known to have a major role in the development of MetS.…”

Section: Discussionmentioning

confidence: 99%

Metabolic Syndrome in Rheumatoid Arthritis and Ankylosing Spondylitis

Kesikburun¹,

Çakçı²

2018

Ankara Medical Journal

View full text Add to dashboard Cite

Objectives: To evaluate and compare the prevalence of insulin resistance and metabolic syndrome (MetS) in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and to determine the relationship of MetS with disease-activities and the factors associated with MetS. Materials and Methods:The cross-sectional study included a total of 174 patients with RA and AS. MetS was defined according to the International Diabetes Federation (IDF) criteria. Insulin resistance was assessed with the Homeostasis Model Assessment (HOMA) Index. The Disease Activity Score including 28 joints (DAS28) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) were used to measure disease activity. Functional status was evaluated using the Health Assessment Questionnaire (HAQ) and the Bath Ankylosing Spondylitis Functional Index (BASFI). Logistic regression analysis was applied to identify predictors of metabolic syndrome. Results: The prevalence of MetS was significantly higher in patients with RA (47%) than in patients with AS (24.56%) (p=0.005). The prevalence of insulin resistance was significantly higher in patients with RA (34.18%) than in patients with AS (17.54%)(p=0.031). No significance difference was found in the disease activity score between RA and AS patients with metabolic syndrome and without metabolic syndrome (p=0.580 and p=0.158, respectively). The number of patients with a higher BASDAI score was greater in AS patients with MetS. Age and body mass index were determined to be predictors for MetS (p=0.015 and p<0.001, respectively). Conclusion: Higher rates of MetS and insulin resistance were seen in RA patients compared to the patients with AS. Better control of the MetS components and disease activity may help to decrease the prevalence of MetS in rheumatic disease. Key words: Metabolic syndrome, rheumatoid arthritis, ankylosing spondylitis, disease activity

show abstract

Metabolic syndrome in patients with rheumatoid arthritis followed at a University Hospital in Northeastern Brazil

Cited by 13 publications

References 39 publications

Percutaneous coronary intervention outcomes in patients with rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis

Percutaneous coronary intervention outcomes in patients with rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis

Systematic review and meta‐analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis

Metabolic Syndrome in Rheumatoid Arthritis and Ankylosing Spondylitis

Contact Info

Product

Resources

About